Wall Street analysts predict that G1 Therapeutics (NASDAQ:GTHX) will report earnings of ($0.64) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for G1 Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.66) and the highest estimate coming in at ($0.62). The firm is scheduled to issue its next quarterly earnings report on Wednesday, May 16th.
On average, analysts expect that G1 Therapeutics will report full year earnings of ($2.47) per share for the current year, with EPS estimates ranging from ($2.55) to ($2.40). For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.84) per share, with EPS estimates ranging from ($3.05) to ($2.48). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, February 21st. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.02).
In other G1 Therapeutics news, insider Mark A. Velleca sold 7,500 shares of G1 Therapeutics stock in a transaction on Monday, April 16th. The shares were sold at an average price of $36.00, for a total transaction of $270,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajesh Malik sold 3,776 shares of G1 Therapeutics stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $20.00, for a total transaction of $75,520.00. The disclosure for this sale can be found here. Insiders have sold a total of 17,302 shares of company stock valued at $554,945 in the last three months.
Several large investors have recently modified their holdings of the business. Alps Advisors Inc. lifted its stake in shares of G1 Therapeutics by 13.1% in the 4th quarter. Alps Advisors Inc. now owns 31,409 shares of the company’s stock valued at $623,000 after purchasing an additional 3,643 shares during the last quarter. Teachers Advisors LLC lifted its stake in shares of G1 Therapeutics by 44.6% in the 4th quarter. Teachers Advisors LLC now owns 13,818 shares of the company’s stock valued at $274,000 after purchasing an additional 4,260 shares during the last quarter. American International Group Inc. acquired a new stake in shares of G1 Therapeutics in the 3rd quarter valued at $130,000. Bank of New York Mellon Corp lifted its stake in shares of G1 Therapeutics by 28.4% in the 4th quarter. Bank of New York Mellon Corp now owns 29,341 shares of the company’s stock valued at $582,000 after purchasing an additional 6,483 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of G1 Therapeutics by 9.3% in the 4th quarter. Geode Capital Management LLC now owns 94,366 shares of the company’s stock valued at $1,872,000 after purchasing an additional 8,061 shares during the last quarter. 42.10% of the stock is owned by institutional investors.
G1 Therapeutics stock opened at $39.13 on Tuesday. G1 Therapeutics has a 52 week low of $12.04 and a 52 week high of $42.78. The company has a market capitalization of $1,272.45 and a P/E ratio of -10.96.
COPYRIGHT VIOLATION WARNING: “Brokerages Expect G1 Therapeutics (GTHX) to Post -$0.64 Earnings Per Share” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://stocknewstimes.com/2018/04/24/brokerages-expect-g1-therapeutics-gthx-to-post-0-64-earnings-per-share.html.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.